SAN DIEGO — Adults with obesity and type 2 diabetes achieved a 14.7% weight loss at 72 weeks with 15 mg tirzepatide, according to data from the SURMOUNT-2 trial presented at the American Diabetes Association Scientific Sessions.In a phase 3 randomized controlled trial, more than 60% of adults with obesity and type 2 diabetes lost at least 10% of their body weight at 72 weeks if they were